AKBA
NASDAQ
US
Akebia Therapeutics, Inc. - Common Stock
$1,38
▼ $-0,03
(-2,13%)
Vol. 1.9M
5
Punteggio di Qualità
fail
Ricavi ✗
Utile netto ✗
>IPO ✗
Cap. mercato
$427.2M
ROE
21,7%
Margine
-7,1%
D/E
461,45
Beta
0,40
52W
$1–$4
Consenso Wall Street
11 analisti · Apr 20265
Acquisto forte
5
Compra
1
Mantieni
0
Vendi
0
Vendita forte
90,9%
Rating Compra
Grafico dei Prezzi
Titoli simili
Chi siamo Akebia Therapeutics, Inc. - Common Stock
Utili
Tasso di battuta: 75,0%
Prossimo report
Mag 06, 2026
Stima EPS: $-0,03
| Trimestre | EPS Stimato | EPS Effettivo | Sorpresa |
|---|---|---|---|
| Mar 2026 | $-0,03 | — | — |
| Dic 2025 | $-0,03 | $-0,05 | $-0,02 |
| Set 2025 | $-0,02 | $0,00 | +$0,02 |
| Giu 2025 | $-0,02 | $0,00 | +$0,02 |
Ricavi e utili trimestrali
| Trimestre | 2024-0… | 2024-1… | 2025-0… | 2025-0… | 2025-0… | 2025-1… |
|---|---|---|---|---|---|---|
| Ricavi | — | $46.5M | $57.3M | $62.5M | $58.8M | $57.6M |
| Utile netto | — | -$22.8M | $6.1M | $247K | $540K | -$12.2M |
Trend fondamentali
| Metrica | 2025-06-30 | 2025-09-02 | 2025-10-02 | 2025-11-03 | 2025-12-03 | 2026-01-02 |
|---|---|---|---|---|---|---|
| ROE (TTM) | 23.6% | 23.6% | 23.6% | 23.6% | 21.7% | 21.7% |
| P/E (TTM) | — | — | — | — | — | — |
| Net Margin | 0.4% | -17.9% | -17.9% | -17.9% | -7.1% | -7.1% |
| Gross Margin | 82.5% | 83.2% | 83.2% | 83.2% | 82.5% | 82.5% |
| D/E Ratio | 641.41 | 161.04 | 641.41 | 641.41 | 461.45 | 461.45 |
| Current Ratio | 1.98 | 1.98 | 1.98 | 1.98 | 1.94 | 1.94 |
Rapporti chiave
ROA (TTM)
-5,1%
P/S (TTM)
1,90
P/B
20,0
EPS (TTM)
$-0,08
CF/Share
$-0,13
Crescita ricavi 3A
-8,9%
52W High
$4,08
52W Low
$1,45
$1,45
Intervallo 52 settimane
$4,08
Salute finanziaria
Flusso di cassa libero
$23.3M
Debito netto
-$133.0M
Liquidità
$184.8M
Debito totale
$51.8M
Aggiornato al Dic 31, 2025
Як AKBA виглядає на тлі конкурентів у Biotechnology?
Група порівняння: Micro-cap Biotechnology (All) · 528 компаній
Оцінка AKBA vs аналоги Biotechnology
P/E
—
▼
0%
sotto
peer
(18,8)
vs Peer
vs Settore
Sottovalutato
P/S
1,9
▼
85%
sotto
peer
(12,9)
vs Peer
vs Settore
Sottovalutato
P/B
20,0
▲
714%
sopra
peer
(2,5)
vs Peer
vs Settore
Sopravvalutato
Дивідендна дохідність
—
▼
0%
sotto
peer
(0,0%)
vs Peer
vs Settore
Rendimento basso
Прибутковість AKBA vs аналоги Biotechnology
ROE
21,7%
▲
132%
sopra
peer
(-67,3%)
vs Peer
vs Settore
Top livello
Net margin
-7,1%
▲
98%
sopra
peer
(-286,8%)
vs Peer
vs Settore
Sotto media
Валова маржа
82,5%
▲
5%
sopra
peer
(78,6%)
vs Peer
vs Settore
Debole
ROA
-5,1%
▲
89%
sopra
peer
(-46,7%)
vs Peer
vs Settore
Top livello
Фінансове здоровʼя AKBA vs аналоги Biotechnology
D/E ratio
461,5
▼
0%
sotto
peer
(0,0)
vs Peer
vs Settore
Debito alto
Поточна ліквідність
1,9
▼
56%
sotto
peer
(4,4)
vs Peer
vs Settore
Liquidità bassa
Beta
0,4
▼
59%
sotto
peer
(1,0)
vs Peer
vs Settore
Più volatile
Радар фундаменталів AKBA
AKBA
Mediana peer
Industria
AKBA прибутковість vs борг
Розмір бульбашки = капіталізація · X = чиста маржа · Y = D/E ratio
AKBA vs аналоги: ключові метрики
Attività insider
NeutralAcquisti
0
Vendite
0
BUTLER JOHN P
Chief Executive Officer · Mar 04
69270 shs
BURKE STEVEN KEITH
Officer · Feb 02
67658 shs
BUTLER JOHN P
Chief Executive Officer · Feb 02
341305 shs
GRUND NICHOLAS
Officer · Feb 02
84829 shs
OSTROWSKI ERIK
Chairman of the Board · Feb 02
34951 shs
MALABRE RICHARD C.
Officer · Feb 02
49524 shs
RUCCI CAROLYN M
Officer · Feb 02
69772 shs
BUTLER JOHN P
Chief Executive Officer · Feb 02
175250 shs
MALABRE RICHARD C.
Officer · Gen 30
79000 shs
RUCCI CAROLYN M
Officer · Gen 30
190000 shs
Ultimo 90 giorni
Principali azionisti
Top 5: 22,4%Blackrock Inc.
7,21%
$25.9M
Vanguard Group Inc
5,98%
$21.5M
State Street Corporation
5,11%
$18.3M
Geode Capital Management, L…
2,34%
$8.4M
Goldman Sachs Group Inc
1,76%
$6.3M
Aggiornato al Dic 31, 2025
Ultime notizie
Nessuna notizia correlata ancora